Introduction
We present the case report of a 59-year-old man with chronic bronchiectasis whose pulmonary flora included Pseudomonas aeruginosa variants that were pan-resistant to licensed agents, and who failed to improve during therapy with high-dose meropenem combined with intravenous (i.v.) and nebulized colistin. Symptoms resolved during named-patient therapy with ceftolozane/tazobactam, a novel cephalosporin b-lactamase inhibitor combination, which was then under regulatory review and has subsequently been licensed by the US Food and Drug Administration for two non-pulmonary indications (Anonymous, 2014) . Ceftolozane/ tazobactam is notable for in vitro activity against P. aeruginosa (Livermore et al., 2009; Shlaes, 2013) and is expected to count towards the Infectious Disease Society of America's 106920 Antimicrobial Initiative (Boucher et al., 2013) .
Case report
The patient had a long history of respiratory illness. He was a heavy smoker (30 day 21 ) for almost 30 years but stopped in 1998. Since 1995, he had been admitted to hospital over 55 times, always for chest infections. He was diagnosed with bronchiectasis in 1997 and with chronic obstructive pulmonary disease (COPD) aureus (MRSA) and he was administered long-term nebulized colistin twice daily thereafter; he also received long-term oxygen therapy at home. By 2014, his selfreported exercise tolerance was 100 yards walking when well. He had received meropenem for 3 weeks around a month before the episode described here, and multiple courses of piperacillin/tazobactam (4.5 g every 8 h) around 4 months previously.
In April 2014 (day 0), the patient was admitted as an emergency case with an exacerbation of bronchiectasis. Symptoms included increased shortness of breath, increased oxygen requirement and increasing green sputum production. Sputum culture on day 1 grew MRSA and P. aeruginosa that was pan-resistant to licensed antibiotics, as confirmed by reference laboratory testing ( . His oxygen requirement rose to 70 % and he produced copious purulent green sputum. Linezolid was stopped on day 14, but the meropenem and i.v. colistin were continued until day 27 when, as there was little else to offer, a palliative care referral was made. The patient was discharged home, continuing on the long-term nebulized colistin and oxygen therapies (4 l min
21
). He was also given a further course of linezolid 600 mg every 12 h p.o., although there was no recent MRSA isolate. His condition continued to deteriorate and he was readmitted on day 30 with shortness of breath at rest.
Further reference laboratory testing of the day 0 P. aeruginosa isolate with unconventional and developmental agents revealed a ceftolozane/tazobactam MIC of 8+4 mg ml 21 (see below), and the combination was sourced from Cubist Pharmaceuticals for 'named-patient' administration. Other antibiotics (linezolid, meropenem and colistin) were stopped and, on day 35, the patient began i.v. treatment with ceftolozane/tazobactam, 2+1 g every 8 h, administered as 1 h infusions. At this stage, his white cell count was 22.6610 9 l 21 and has CRP was 152 mg ml 21 .
Progressive improvement was achieved during the ceftolozane/tazobactam therapy and, by the end of a 14-day course (day 49), the patient had ceased to produce sputum, no longer required supplemental oxygen and was breathing normally on air. His white cell count and CRP returned to baseline values of 14.7610 9 l 21 and 21 mg ml, respectively. On day 58, he was discharged on linezolid 600 mg twice a day for 2 weeks (although, again, there was no recent MRSA isolate) and continued on long-term nebulized colistin. He was re-admitted on day 100 and remained in hospital until day 118 with a further infective exacerbation of bronchiectasis, for which he was administered meropenem 1 g every 8 h and gentamicin 5 mg kg 21 every 24 h, and also linezolid following re-isolation of MRSA on day 105. He was discharged on day 118, again on the nebulized colistin and with the infection controlled. He died on day 153. . Referred isolates were fingerprinted by variable number tandem repeat (VNTR) typing (Turton et al., 2010) .
Microbiological investigations
Local susceptibility results, which spanned exacerbations in late 2013 as well as the proximate episode, varied over time, with a trend to increasing resistance and with no agent retaining consistent activity (Table 1 ). The day 1 isolate received by the reference laboratory was resistant to all licensed anti-pseudomonal agents, including meropenem and colistin, which the patient was then receiving. This prompted testing of ceftolozane/tazobactam, where the MIC was recorded as 8+4 mg ml
21
, although with the majority population inhibited at 2+4 mg ml 21 with only isolated colonies growing on the 2 and 4 mg ml 21 plates. Typing revealed that the fully susceptible day 2181 isolate and the highly resistant day 1 isolates shared the same VNTR profile (8, 3, 4, 5, 2, 3, 5, 2, 11), implying that a single infective strain was present, with fluctuating populations of variably resistant and susceptible variants.
Discussion
This patient, with a long history of pulmonary disease and treatment, had a complex pulmonary P. aeruginosa flora. As in cystic fibrosis (Ashish et al., 2013) , it is likely that this variation reflected repeated antibiotic use selecting for multiple subpopulations of the infective strain in the lung, varying in resistance but retaining a consistent VNTR type. The patient's exacerbation around day 0-1 involved a variant resistant to all licensed antibiotics and, in keeping with these in vitro results, he responded poorly to a meropenem/colistin regimen. Given this therapeutic failure, we afford little significance to isolating variants on days 11 and 22 (i.e. during the meropenem/colistin therapy) that were susceptible to one or both of these agents. This led to compassionate 'named-patient' therapy with ceftolozane/ tazobactam, leading to a considerable clinical improvement.
There were no breakpoints available at the time when this patient was treated, but the combination has good penetration to the lung (Chandorkar et al., 2012) and the MIC R. Soliman and others Table 1 . ; a few isolated colonies only inhibited at 8 mg
Susceptibility testing results

Antibiotic
Bold font is used for reference laboratory MIC data and interpretation.
Successful treatment of 'pan-resistant' P. aeruginosa found (8 mg ml
21
, Table 1 ) was inferred to predict susceptibility based on: (i) analogy to ceftazidime, which has the same maximum dosage and a shorter half-life, with BSAC/EUCAST breakpoints of: sensitive, #8; resistant, .8 mg ml 21 (European Committee on Antimicrobial Susceptibility Testing, 2014) and (ii) pharmacodynamic modelling, indicating 1 log killing up to an MIC of 16 mg ml 21 (Lepak et al., 2014; VanScoy et al., 2014) . As the MIC nevertheless was high compared with typical ceftolozane values of 0.25-0.5 mg ml 21 for P. aeruginosa (Livermore et al., 2009 ), a 2+1 g every 8 h regimen was employed, as presently in phase III trials for ventilator pneumonia, rather than the 1+0.5 g every 8 h regimen used in phase III urinary and intra-abdominal trials. The recent US Food and Drug Authority license for the latter two indications indicates P. aeruginosa breakpoints of sensitive, #4 mg ml , predicated on a 1+0.5 g every 8 h regimen (Anonymous, 2104) , and the decision to use the higher-dose regimen is further justified with reference to these criteria.
In vitro studies show that the MICs of ceftolozane for P. aeruginosa typically are approximately four-to eightfold lower than for ceftazidime, which previously was the most active licensed cephalosporin against this species. MICs of ceftolozane for P. aeruginosa strains with upregulated efflux or derepressed AmpC b-lactamase rarely exceed 2-4 mg ml
, whereas ceftazidime MICs for isolates with these mechanisms range from 16 to 128 mg ml 21 (Livermore et al., 2009; Juan et al., 2010) ; High-level ceftolozane resistance in P. aeruginosa appears confined to strains with metallocarbapenemases, PER and VEB extended-spectrum blactamases and some cystic fibrosis isolates with complex mixtures of mechanisms (Livermore et al., 2009; Juan et al., 2010) . Tazobactam protects ceftolozane against the extended-spectrum b-lactamases of Enterobacteriaceae but has limited relevance to anti-pseudomonal activity (Shlaes, 2013) . Given these data, and assuming regulatory approval, it seems likely that ceftolozane/tazobactam will often be the most active agent in vitro against difficult P. aeruginosa strains from chronic pulmonary infections, including cystic fibrosis and COPD. We urge that trials should be done in these settings to validate its therapeutic potential and to test whether the success described here is representative.
